200 related articles for article (PubMed ID: 31831337)
1. Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action.
Laselva O; Eckford PD; Bartlett C; Ouyang H; Gunawardena TN; Gonska T; Moraes TJ; Bear CE
J Cyst Fibros; 2020 Sep; 19(5):717-727. PubMed ID: 31831337
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of Combinatorial Pharmacological Treatments to Correct Nonsense Mutations in the CFTR Gene.
Venturini A; Borrelli A; Musante I; Scudieri P; Capurro V; Renda M; Pedemonte N; Galietta LJV
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769402
[TBL] [Abstract][Full Text] [Related]
3. Nonsense-mediated RNA Decay Pathway Inhibition Restores Expression and Function of W1282X CFTR.
Keenan MM; Huang L; Jordan NJ; Wong E; Cheng Y; Valley HC; Mahiou J; Liang F; Bihler H; Mense M; Guo S; Monia BP
Am J Respir Cell Mol Biol; 2019 Sep; 61(3):290-300. PubMed ID: 30836009
[TBL] [Abstract][Full Text] [Related]
4. Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations.
Mutyam V; Sharma J; Li Y; Peng N; Chen J; Tang LP; Falk Libby E; Singh AK; Conrath K; Rowe SM
Am J Respir Cell Mol Biol; 2021 May; 64(5):604-616. PubMed ID: 33616476
[TBL] [Abstract][Full Text] [Related]
5. Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy.
Kim YJ; Nomakuchi T; Papaleonidopoulou F; Yang L; Zhang Q; Krainer AR
Nat Commun; 2022 May; 13(1):2978. PubMed ID: 35624092
[TBL] [Abstract][Full Text] [Related]
6. Decreased mRNA and protein stability of W1282X limits response to modulator therapy.
Aksit MA; Bowling AD; Evans TA; Joynt AT; Osorio D; Patel S; West N; Merlo C; Sosnay PR; Cutting GR; Sharma N
J Cyst Fibros; 2019 Sep; 18(5):606-613. PubMed ID: 30803905
[TBL] [Abstract][Full Text] [Related]
7. Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product.
Haggie PM; Phuan PW; Tan JA; Xu H; Avramescu RG; Perdomo D; Zlock L; Nielson DW; Finkbeiner WE; Lukacs GL; Verkman AS
J Biol Chem; 2017 Jan; 292(3):771-785. PubMed ID: 27895116
[TBL] [Abstract][Full Text] [Related]
8. Use of adenine base editing and homology-independent targeted integration strategies to correct the cystic fibrosis causing variant, W1282X.
Mention K; Cavusoglu-Doran K; Joynt AT; Santos L; Sanz D; Eastman AC; Merlo C; Langfelder-Schwind E; Scallan MF; Farinha CM; Cutting GR; Sharma N; Harrison PT
Hum Mol Genet; 2023 Nov; 32(23):3237-3248. PubMed ID: 37649273
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation.
Oren YS; Avizur-Barchad O; Ozeri-Galai E; Elgrabli R; Schirelman MR; Blinder T; Stampfer CD; Ordan M; Laselva O; Cohen-Cymberknoh M; Kerem E; Bear CE; Kerem B
J Cyst Fibros; 2022 Jul; 21(4):630-636. PubMed ID: 34972649
[TBL] [Abstract][Full Text] [Related]
10. Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids.
de Poel E; Spelier S; Suen SWF; Kruisselbrink E; Graeber SY; Mall MA; Weersink EJM; van der Eerden MM; Koppelman GH; van der Ent CK; Beekman JM
J Cyst Fibros; 2022 Mar; 21(2):246-253. PubMed ID: 34666947
[TBL] [Abstract][Full Text] [Related]
11. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.
Linde L; Boelz S; Nissim-Rafinia M; Oren YS; Wilschanski M; Yaacov Y; Virgilis D; Neu-Yilik G; Kulozik AE; Kerem E; Kerem B
J Clin Invest; 2007 Mar; 117(3):683-92. PubMed ID: 17290305
[TBL] [Abstract][Full Text] [Related]
12. Exon-skipping antisense oligonucleotides for cystic fibrosis therapy.
Kim YJ; Sivetz N; Layne J; Voss DM; Yang L; Zhang Q; Krainer AR
Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35017301
[TBL] [Abstract][Full Text] [Related]
13. CFTR mRNAs with nonsense codons are degraded by the SMG6-mediated endonucleolytic decay pathway.
Sanderlin EJ; Keenan MM; Mense M; Revenko AS; Monia BP; Guo S; Huang L
Nat Commun; 2022 Apr; 13(1):2344. PubMed ID: 35487895
[TBL] [Abstract][Full Text] [Related]
14. Restoration of W1282X CFTR activity by enhanced expression.
Rowe SM; Varga K; Rab A; Bebok Z; Byram K; Li Y; Sorscher EJ; Clancy JP
Am J Respir Cell Mol Biol; 2007 Sep; 37(3):347-56. PubMed ID: 17541014
[TBL] [Abstract][Full Text] [Related]
15. Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor.
Xue X; Mutyam V; Tang L; Biswas S; Du M; Jackson LA; Dai Y; Belakhov V; Shalev M; Chen F; Schacht J; J Bridges R; Baasov T; Hong J; Bedwell DM; Rowe SM
Am J Respir Cell Mol Biol; 2014 Apr; 50(4):805-16. PubMed ID: 24251786
[TBL] [Abstract][Full Text] [Related]
16. Robust Stimulation of W1282X-CFTR Channel Activity by a Combination of Allosteric Modulators.
Wang W; Hong JS; Rab A; Sorscher EJ; Kirk KL
PLoS One; 2016; 11(3):e0152232. PubMed ID: 27007499
[TBL] [Abstract][Full Text] [Related]
17. Synergy between Readthrough and Nonsense Mediated Decay Inhibition in a Murine Model of Cystic Fibrosis Nonsense Mutations.
McHugh DR; Cotton CU; Hodges CA
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396210
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Cas9 and Cas12a CRISPR editing methods to correct the W1282X-CFTR mutation.
Santos L; Mention K; Cavusoglu-Doran K; Sanz DJ; Bacalhau M; Lopes-Pacheco M; Harrison PT; Farinha CM
J Cyst Fibros; 2022 Jan; 21(1):181-187. PubMed ID: 34103250
[TBL] [Abstract][Full Text] [Related]
19. Open reading frame correction using splice-switching antisense oligonucleotides for the treatment of cystic fibrosis.
Michaels WE; Pena-Rasgado C; Kotaria R; Bridges RJ; Hastings ML
Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35017302
[No Abstract] [Full Text] [Related]
20. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
